Asymmetric Catalysis on Industrial Scale (ePub)

PART I: New Processes for Existing Active Compounds (APIs) SOME RECENT EXAMPLES IN DEVELOPING BIOCATALYTIC PHARMACEUTICAL PROCESSES Introduction Levetiracetam (Keppra®) Atorvastatin (Lipitor®) Pregabalin (Lyrica®) Conclusion ENANTIOSELECTIVE HYDROGENATION: APPLICATIONS IN PROCESS R&D OF PHARMACEUTICALS Introduction Carbonyl Hydrogenations Imine Hydrogenation Conclusion CHIRAL LACTONES BY ASYMMETRIC HYDROGENATION ? A STEP FORWARD IN (+)-BIOTIN PRODUCTION Introduction: (+)-Biotin as an Example for the Industrial Production of Vitamins Commercial Syntheses and Other Routes to (+)-Biotin by Total Synthesis Catalytic Asymmetric Reduction of Cyclic Anhydride to D-Lactone Conclusion BIOCATALYTIC ASYMMETRIC OXIDATION FOR THE PRODUCTION OF BICYCLIC PROLINE PEPTIDOMIMETICS Introduction Development of Routes to 1 and 2 Asymmetric Biocatalytic Amine Oxidation Enzyme Evolution ? Current State of the Art Amine Oxidase Evolution Chemical Development Optimization of Cyanation Conclusion THE ASYMMETRIC REDUCTION OF HETEROCYCLIC KETONES ? A KEY STEP IN THE SYNTHESIS OF POTASSIUM-COMPETITIVE ACID BLOCKERS (P-CABs) Potassium-Competitive Acid Blockers ? A New Option for the Treatment of Acid-Related Diseases Discovery and Development of 7H-8,9-Dihydropyrano[2,3-c]imidazo[1,2-a]pyridines as Potassium-Competitive Acid Blockers Noyori-Type Catalysts for the Asymmetric Reduction of Prochiral Ketones Research Overview Asymmtric Reduction of Ketones Bearing the Imidazo[1,2-a]pyridine Skeleton Asymmetric Reduction of Ketones Bearing the 3,6,7,8-Tetrahydrochromenol[7,8-d]imidazole Skeleton Large-Scale Asymmetric Synthesis of the 3,6,7,8-Tetrahydrochromeno[7,8-d]imidazole BYK 405879 Conclusions PART II: Processes for Important Building Blocks APPLICATION OF A MULTIPLE-ENZYME SYSTEM FOR CHIRAL ALCOHOL PRODUCTION Introduction Construction of an Enzymatic Reduction System Enzymatic Stereoinversion System CHEMOENZYMATIC ROUTE TO THE SIDE-CHAIN OF ROSUVASTATIN Introduction Route Selection Process

Hans-Ulrich Blaser carried out his doctoral research with A. Eschenmoser at the Federal Institute of Technology (ETH) Zürich, where he received the Ph.D. degree in 1971. Between 1971 and 1975 he held postdoctoral positions at the University of Chicago (J. Halpern), Harvard University (J.A. Osborn), and Monsanto (Zürich). During 20 years at Ciba-Geigy (1976-1996) he gained practical experience at R&D in the fine chemicals and pharmaceutical industry, which continued at Novartis (1996-1999) and at Solvias where he presently is chief technology officer.

Hans-Jürgen Federsel is a renowned specialist in the field of process R&D with a professional career spanning over 30 years. Starting off as bench chemist in Astra at the major Swedish site in Södertälje, he climbed the ranks to occupy positions both as line and project manager. After the merger that formed AstraZeneca, he became Head of Projects Management at the aforementioned location and was then appointed to the newly created role as Director of Science in Global Process R&D in 2004. In connection with this, he was also given the prestigious title Senior Principal Scienstist. His strong academic links have been further developed over the years after obtaining the PhD in Organic Chemistry at the Royal Institute of Technology in Stockholm, which was led to his being awarded an Associate Professorship there.
His long-lasting links to this Institute has brought him a seat on the Board of the School of Chemical Science and Engineering from 2005. Publishing in peer reviewed journals and books and frequent lecturing has rendered fame to his name that goes far beyond the limits of the own company and Dr. Federsel enjoys invitations from all over the world to share learning and experience from his broad knowledge base on process R&D. In 2009 he was elected to the Royal Swedish Academy of Engineering Sciences (IVA).

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.